See more : Hanwha General Insurance Co., Ltd. (000370.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Northern Genesis Acquisition Corp. III (NGC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Northern Genesis Acquisition Corp. III, a leading company in the Shell Companies industry within the Financial Services sector.
- Signature Eyewear, Inc. (SEYE) Income Statement Analysis – Financial Results
- PT Gudang Garam Tbk (GGNPF) Income Statement Analysis – Financial Results
- Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) Income Statement Analysis – Financial Results
- Polski Holding Nieruchomosci S.A. (PHN.WA) Income Statement Analysis – Financial Results
- Astra Microwave Products Limited (ASTRAMICRO.NS) Income Statement Analysis – Financial Results
Northern Genesis Acquisition Corp. III (NGC)
About Northern Genesis Acquisition Corp. III
Northern Genesis Acquisition Corp. III does not have significant operations. It focuses to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Kansas City, Missouri.
| Metric | 2021 |
|---|---|
| Revenue | 0.00 |
| Cost of Revenue | 0.00 |
| Gross Profit | 0.00 |
| Gross Profit Ratio | 0.00% |
| Research & Development | 0.00 |
| General & Administrative | 0.00 |
| Selling & Marketing | 0.00 |
| SG&A | 0.00 |
| Other Expenses | 1.59M |
| Operating Expenses | 1.59M |
| Cost & Expenses | 1.59M |
| Interest Income | 12.17K |
| Interest Expense | 0.00 |
| Depreciation & Amortization | -4.30M |
| EBITDA | -5.89M |
| EBITDA Ratio | 0.00% |
| Operating Income | -1.59M |
| Operating Income Ratio | 0.00% |
| Total Other Income/Expenses | 3.95M |
| Income Before Tax | 2.36M |
| Income Before Tax Ratio | 0.00% |
| Income Tax Expense | 350.53K |
| Net Income | 2.36M |
| Net Income Ratio | 0.00% |
| EPS | 0.13 |
| EPS Diluted | 0.13 |
| Weighted Avg Shares Out | 18.59M |
| Weighted Avg Shares Out (Dil) | 18.59M |
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Northern Graphite Comments on U.S. Tariffs on Graphite from China
Source: https://incomestatements.info
Category: Stock Reports